Overview

NodThera is a clinical stage biotech company that is leveraging our expertise in the field of the NLRP3 inflammasome to discover and develop novel anti-inflammatory drugs designed to provide new treatment options for patients suffering a range of chronic inflammatory diseases. NodThera’s lead product candidates are completing IND-enabling studies and advancing through clinical development and we have raised just over $100M in venture capital financing from leading healthcare investors. NodThera is headquartered in Lexington, MA with sites in Cambridge, UK and Seattle, WA.

See all Members